Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Enteris Biopharma to Create Oral Metabolic Peptide in New Partnership

By Drug Discovery Trends Editor | January 30, 2017

 Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced the initiation of a clinical manufacturing services agreement with KeyBioscience AG, a wholly-owned subsidiary of Nordic Bioscience, whereby Enteris will leverage its proprietary Peptelligence™ platform to advance the development of a proprietary metabolic peptide for the treatment of various indications, including diabetes, obesity, and other metabolic disorders.

Under the terms of the agreement, Enteris BioPharma will leverage its Peptelligence™ platform to manufacture and characterize three oral tablet prototypes of KeyBioscience’s metabolic peptide, as well as become the exclusive provider of finished product for use in pre-clinical and proof-of-concept clinical trial research.

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, commented, “This agreement with Nordic Bioscience showcases the value of our Peptelligence™ platform to develop and enable the oral delivery of promising peptide and small molecule therapeutics.  Additionally, it highlights our unique ability to partner with global pharmaceutical companies to develop drug products that address significant patient care and market opportunities. We are truly excited to be working with Key Bioscience on this new class of compounds.”

Morten Karsdal, Chief Executive Officer of Nordic Bioscience, remarked, “The ability to deliver our proprietary DACRA peptides orally offers KeyBioscience the potential to bring to market a new therapeutic choice for the treatment of metabolic disorders, which is a significant market opportunity. An oral delivery using Enteris’s Peptelligence™ platform and manufacturing capabilities will be a value driver and a key to success. We look forward to progress with an oral formulation of our DACRA peptides into clinical trials and potential commercialization.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50